Union Acquisition Corp. Announces Date of Extraordinary General Meeting of Shareholders and Record Date
Union Acquisition Corp. (NYSE: LTN) (“UAC”), a special purpose acquisition company, has set the date of its extraordinary general meeting of shareholders (“extraordinary general meeting”) to vote on the previously announced business combination with Bioceres, Inc., for Wednesday, February 27, 2019. The date of the extraordinary general meeting was previously disclosed in the Pre-Effective Amendment No.1 to UAC’s Registration Statement on Form S-4, filed with the Securities and Exchange Commission (“SEC”) on February 7, 2019. The extraordinary general meeting will be held at 10:00 a.m. local time at the offices of Arnold & Porter Kaye Scholer LLP, located at 250 West 55th Street Avenue, New York, New York 10019. The record date for those eligible to receive notice of and to vote at the extraordinary general meeting is February 7, 2019 (the “Record Date”). UAC expects to mail its definitive proxy statement/prospectus and related information regarding the business combination and the extraordinary general meeting on or about February 11, 2019.
Ensuring Your Vote is Counted
UAC advises holders of its securities to move their securities into accounts that do not permit the lending of securities, so called cash accounts or segregated accounts, and out of accounts that permit the lending of securities, such as margin accounts. These steps are designed to ensure that votes related to ordinary shares beneficially owned by shareholders are properly counted. Beneficial owners of ordinary shares that have been lent out (either with or without the beneficial owners’ knowledge) are not permitted to vote those shares.
About Union Acquisition Corp.
Union Acquisition Corp. is a blank check company organized for the purpose of effecting a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization, or other similar business combination with one or more businesses or entities. UAC’s efforts to identify a prospective target business are not limited to any particular industry or geographic region, although the Company has focused on target businesses located in Latin America. The Company is led by Juan Sartori, Chairman of the Board of the Company and Chairman and founder of Union Group International Ltd., and Kyle P. Bransfield, Chief Executive Officer of the Company and Partner of Atlantic-Pacific Capital, Inc.
Forward Looking Statements
This communication includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “forecast,” “intend,” “seek,” “target,” “anticipate,” “believe,” “expect,” “estimate,” “plan,” “outlook,” and “project” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Such forward-looking statements include estimated financial information. Such forward-looking statements with respect to revenues, earnings, performance, strategies, prospects and other aspects of the businesses of UAC, Bioceres or the combined company after completion of the business combination are based on current expectations that are subject to known and unknown risks and uncertainties, which could cause actual results or outcomes to differ materially from expectations expressed or implied by such forward- looking statements. These factors include, but are not limited to: (1) the occurrence of any event, change or other circumstances that could give rise to the termination of the exchange agreement entered into in connection with the proposed business combination (the “Exchange Agreement”) and the proposed business combination contemplated therein; (2) the inability to complete the transactions contemplated by the Exchange Agreement due to the failure to obtain approval of the shareholders or other conditions to closing in the Exchange Agreement; (3) the ability of UAC to continue to meet applicable NYSE listing standards; (4) the risk that the proposed business combination disrupts current plans and operations of Bioceres as a result of the announcement and consummation of the transactions described in the Exchange Agreement; (5) the ability to recognize the anticipated benefits of the proposed business combination, which may be affected by, among other things, competition, the ability of the combined company to grow and manage growth profitably, maintain relationships with customers and suppliers and retain its management and key employees; (6) costs related to the proposed business combination; (7) changes in applicable laws or regulations; (8) the possibility that Bioceres may be adversely affected by other economic, business, and/or competitive factors; and (9) other risks and uncertainties indicated from time to time in the definitive registration statement of UAC in connection with the proposed business combination and the proxy statement/prospectus contained therein, including those under “Risk Factors” therein, and other documents filed or to be filed with the SEC by UAC. Investors are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made. UAC and Bioceres undertake no commitment to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise. Investors should carry out their own due diligence in connection with the assumptions contained herein. The forward-looking statements in this communication speak only as of the date of this communication. Although UAC may from time to time voluntarily update its prior forward-looking statements, it disclaims any commitment to do so whether as a result of new information, future events, changes in assumptions or otherwise except as required by applicable securities laws.
Additional Information and Where to Find It
In connection with the proposed business combination between Bioceres and UAC, UAC has filed with the SEC a Registration Statement on Form S-4, a preliminary proxy statement/prospectus and a definitive proxy statement/prospectus, forming a part thereof. UAC’s shareholders and other interested persons are advised to read the preliminary proxy statement/prospectus, and amendments thereto, and the definitive proxy statement/prospectus in connection with UAC’s solicitation of proxies for its extraordinary general meeting of shareholders to be held to approve the proposed business combination because the proxy statement/prospectus contains important information about the proposed business combination, UAC and Bioceres. The definitive proxy statement/prospectus will be mailed to UAC’s shareholders as of the Record Date on or about February 11, 2019.
Shareholders will also be able to obtain a copy of the preliminary and definitive Registration Statement, without charge, at the SEC’s website at http://sec.gov or by directing a request to: Union Acquisition Corp., 444 Madison Avenue, Floor 34, New York, NY 10022. UAC shareholders will be able to obtain free copies of these documents and other documents containing important information about UAC and Bioceres, once such documents are filed with the SEC.
No Offer or Solicitation
This announcement is for informational purposes only and is neither an offer to sell, nor a solicitation of an offer to buy any securities or the solicitation of any vote in any jurisdiction pursuant to the proposed transactions or otherwise, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in which the offer, solicitation, or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended.
Participants in the Solicitation
UAC and its directors, executive officer, certain of its shareholders prior to its initial public offering and other members of its management and employees and affiliates, and Bioceres, its directors and management may be deemed to be participants in the solicitation of proxies from UAC’s shareholders in connection with the proposed business combination. Shareholders are urged to carefully read the Registration Statement regarding the proposed business combination because it contains important information, including information regarding the persons who may, under the rules of the SEC, be deemed participants in the solicitation of UAC’s shareholders in connection with the proposed business combination, as well as information about UAC’s executive officers and directors.
Kyle Bransfield, Chief Executive Officer, UAC
+1 212 981 0633
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
c-LEcta: Successful Product Business in the First Half of 201922.8.2019 11:06:00 EEST | Press release
c-LEcta, a globally active biotechnology company with technology leadership in enzyme engineering and bioprocess development, successfully expanded its product business in the first half of 2019. Besides sales increases across the entire portfolio, the company was granted many new patents. While the patent portfolio still comprised 59 granted patents at the end of the first half of 2018, the Leipzig-based company now holds more than 80 patents. c-LEcta’s DENARASE®, which is used for the necessary removal of nucleic acids from biopharmaceutical products, performed particularly well. DENARASE® is the most efficient technology on the market for meeting the stringent regulatory requirements for biopharmaceutical products. Sales of this product increased by 164% year-on-year in the first half of 2019. The other products in c-LEcta’s portfolio also performed very well and contributed to the positive development of the product business. c-LEcta now markets its self-developed products in 25 co
MobileIron Named a Leader Again in the Second Gartner Magic Quadrant for Unified Endpoint Management Tools22.8.2019 10:00:00 EEST | Press release
MobileIron (NASDAQ:MOBL), the company that introduced the industry’s first mobile-centric, zero trust platform for the enterprise, today announced that it has been positioned as a Leader for the second consecutive year in the Gartner Magic Quadrant for Unified Endpoint Management Tools. The report evaluated 11 vendors based on completeness of vision and ability to execute. “To us, it’s an honor to be recognized once again as a Leader in Gartner’s Magic Quadrant for Unified Endpoint Management Tools,” said Simon Biddiscombe, CEO, MobileIron. “We have continued to innovate and expand upon our UEM platform to keep up with the demands of today’s digital businesses. Earlier this year, we introduced a revolutionary zero sign-on experience to eliminate passwords and make the world’s most ubiquitous product – the mobile device – your ID and secure access to the enterprise built on our leadership foundation in UEM. Mobile and cloud technologies have driven a dramatic change in organizations acr
Miracor Medical Granted FDA Breakthrough Device Designation for the PiCSO Impulse System22.8.2019 09:00:00 EEST | Press release
Miracor Medical SA (Miracor Medical) has been granted Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA) for its PiCSO® Impulse System for treatment of STEMI patients. The FDA Breakthrough Device designation is intended to speed time to market for treatments of life-threatening or irreversibly debilitating diseases or conditions and recognizes the novelty of the PiCSO Impulse System and its potential to benefit patients with anterior STEMI heart attacks. The Centers for Medicare & Medicaid Services (CMS) also recently acknowledged the importance of this designation by establishing an alternative reimbursement pathway for products that receive FDA marketing authorization and held the Breakthrough Designation. PiCSO therapy is provided by interventional cardiologists during PCI (Percutaneous Coronary Intervention) in patients experiencing ST-elevated myocardial infarction (STEMI). The PiCSO Impulse System clears the coronary microcirculation by intermittently
Mori Building Unveils Massive Urban Regeneration Project in Central Tokyo22.8.2019 07:00:00 EEST | Press release
Mori Building Co., Ltd., a leading urban landscape developer, has begun construction on its “Toranomon-Azabudai District Category 1 Urban Redevelopment Project,” a massive urban regeneration project aimed at revitalizing a large area of central Tokyo. A groundbreaking ceremony was held on August 5 and project completion is scheduled for the end of March 2023. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190821005445/en/ Image of Office Lobby (Graphic: Business Wire) The core concept of the Toranomon-Azabudai Project is that of a “Modern Urban Village,” a unique neighborhood that will combine the sophistication of a megalopolis with the intimacy of a small village in the heart of Tokyo. It will cover an area of approximately 8.1 hectares, similar to that of New York’s Rockefeller Center, and will feature extensive greenery totaling 24,000 m2 including a 6,000 m2 central square. Total floor area will be 860,400 m2, including
Mundipharma Announces the Licence Extension Submission for Invokana® (canagliflozin) and Vokanamet® (canagliflozin and metformin) to the European Medicines Agency22.8.2019 02:01:00 EEST | Press release
STRICTLY FOR EUROPEAN MEDICAL AND PHARMACEUTICAL TRADE MEDIA ONLY As the European distributor of Invokana® (canagliflozin) and Vokanamet® (canagliflozin and metformin), Mundipharma welcomes the news that the European Medicines Agency (EMA) has accepted the licence extension submission for these two medicines to treat stage 2 or stage 3 chronic kidney disease (CKD) and albuminuria as an adjunct to standard of care in adults with type 2 diabetes mellitus (T2DM). The submission is based on the results from the landmark Phase III CREDENCE study1 which evaluated the efficacy and safety of canagliflozin versus placebo in this high-risk patient population when used in addition to standard of care. “Chronic kidney disease is a serious complication of type 2 diabetes, which can increase patients’ risk of developing end-stage renal disease and may reduce their life expectancy by several years.” said Dr Vinicius Gomes de Lima, European Medical Affairs Lead, Mundipharma. “If approved, this licence
Triton Digital Releases Webcast Metrics Rankings for the Top Digital Audio Properties for April 201921.8.2019 23:00:00 EEST | Press release
Triton Digital®, the global technology and services leader to the digital audio and podcast industry, released today its monthly Webcast Metrics® rankers for April 2019. The global rankers, in addition to the U.S., LATAM, and EMEA regional rankers provide insight into the top-performing streaming audio stations and networks around the world for the month of April. The full results of the Global & Regional Rankers for April 2019 can be found here: https://www.tritondigital.com/resources/monthly-rankers/rankers-archive The Webcast Metrics streaming measurement service is the industry standard for online audio consumption data. It provides credible, validated data that enables audio publishers around the world to analyze the consumption of their audio content by daypart, device type, geography, distribution platform, and more. About Triton Digital Triton Digital® is the global technology and services leader to the digital audio and podcast industry. Operating in more than 40 countries, Tr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom